Engitix, a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has appointed Matthew Edwards as Senior Vice President of Discovery Sciences and Emma Huang, as Vice President of Data Sciences.
Matthew Edwards
Dr Edwards is a seasoned drug discovery leader with extensive industry experience. He has developed six clinically-enabled novel therapeutics and has deep immunology and oncology domain expertise.
He joins Engitix from Johnson & Johnson, where he was the Global Head of Discovery and Translational Sciences for Interventional Oncology. In this role, he developed a portfolio of immuno-oncology assets primarily designed to be delivered intra-tumorally, which included low molecular weight drugs, therapeutic antibodies and RNA therapeutics.
Prior to this, further industrial drug discovery experience included leadership positions at Novartis, and GSK in the respiratory and immunology therapeutics areas.
At Engitix he will be responsible for leading the company’s internal drug discovery scientific strategy.
Emma Huang
Dr Huang brings to Engitix a strong track record of identifying and executing on transformative opportunities harnessing data science to accelerate the development of novel therapies and solutions for patients. She joins Engitix from Johnson & Johnson, where she served as Head of Data Sciences for Interventional Oncology.
In this role, she shaped and built key data science capabilities including the data, analytics, platforms and partnerships necessary to support discovery and translational biomarker efforts.
With over 40 peer reviewed papers and a career spanning academia, government and industry, Emma has consistently demonstrated her commitment to scientific advancement and collaboration through roles such as Deputy Chair of the MRC Population & Systems Medicine Board.
At Engitix she will be responsible for leading the company’s data and analytics strategy supporting platform development, internal drug discovery pipeline and external partnerships.
Dr Christopher Stevenson CSO at Engitix, said: “I am delighted to welcome Matt and Emma to Engitix. We have created the roles of SVP Discovery and VP Data Sciences to expand our leadership team and capabilities. The expertise Matt and Emma bring will galvanise the team’s focus on translating the insights gained from Engitix’ proprietary platform technologies into transformational therapies for patients.”
